



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 16, 2022; October 2, 2023

ENJAYMO® (sutimlimab-jome)

LENGTH OF AUTHORIZATION: 6 months

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Patient must have a diagnosis of cold agglutinin disease (CAD); **AND**
- **Medication was prescribed to treat hemolysis associated with CAD.**
- Prescribed or in consultation with a hematologist.
- Patient has history of blood transfusion within the past year.

CONTINUATION OF THERAPY

- Patient met initial review criteria.
- Documentation of positive clinical response.
- Dosing is appropriate as per labeling or is supported by compendia.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 1,100 mg/22 mL (50 mg/mL) single-dose vial.